Healome Therapeutics clôture une levée de fonds d'amorçage de 2 millions de livres sterling menée par Empirical Ventures afin de faire progresser sa technologie de matrice de collyre destinée au traitement des maladies de la surface oculaire

Eye drop matrix technologyPositive

AI Analysis

Summary

Healome Therapeutics, a University of Birmingham spinout, closed a £2 million seed funding round led by Empirical Ventures to advance its proprietary eye drop matrix technology for treating ocular surface diseases.

Importance:4/10

Sentiment:

0.70

fundingseed roundophthalmologyeye drop technologyuniversity spinout

Related Companies

$SURF

Read the original article

Published by PR Newswire Biotech on July 7, 2026 11:07 AM

Read Original